TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S.
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med Izervay has nabbed a much-needed label update from the FDA. The agency lifted ...
Syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause irreversible ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic atrophy (GA) med Izervay has taken a few beatings in recent months. Still, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results